Liquidia Corporation (NASDAQ: LQDA) is a Healthcare company (Medical - Pharmaceuticals) with a market capitalization of $5.2B. The Maz Rating grades it against the other companies in its sector.
About three months ago (July 2, 2026), Liquidia Corporation had a Maz Rating of 4.90 out of 5 (A, Strong Buy), ranked against the other companies in its sector. Its strongest factor then was Momentum (4.94), among the strongest in its sector; its weakest was Valuation (1.19), among the most expensive in its sector. The other factors: Growth 4.81 (among the strongest in its sector); Profitability 4.62 (among the strongest in its sector); Financial Health 3.68 (above most of its sector). The current rating is for members: log in to see it.
At $58.12, Liquidia Corporation trades at 8.4x sales. Over the last twelve months it generated about $626M of revenue and a net loss of $93M. It runs a gross margin of 92.7%, an operating margin of -15.6% and a net margin of -15.1%. It shows return on equity of -116.6%, return on invested capital of -55.7% and a free cash flow yield of 3.8%. On the balance sheet: a debt-to-equity ratio of -6.64 and a current ratio of 1.02. Over the past 52 weeks the share price ranged from $22.31 to $93.61, with a beta of 0.54.
Liquidia Corporation does not currently pay a dividend.
10 Wall Street analyst ratings cover the stock: 7 Buy, 2 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.